

# Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)

NCT05769348

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	University of Michigan
Enrollment	80 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Male or female, aged 18 to 65 (inclusive)
- Patients must have Episodic migraines that started before the age of 50, and currently experience:
- Chronic migraine (ICHD-3-beta), headache occurring on 15 days/month for more than six months, which, on at least eight days/month, has the features of a migraine headache.
- Episodic migraine (low frequency), specifically those with headache occurring less than 8 days/month.
- Willing to limit the introduction of new treatments and medications during the study period.

### Exclusion (13)

- Significantly greater pain in body sites other than the head
- Active, untreated major concurrent systemic illness other than migraine
- Medical conditions that can impair health status independent of migraine (including cardiopulmonary disorders, malignancy, uncontrolled endocrine or allergies)
- Systemic rheumatic disorders (i.e., rheumatoid arthritis, systemic lupus erythematosus, gout, and fibromyalgia);
- History or current evidence of a psychotic disorder (e.g., bipolar disorder, schizophrenia) or severe major depression, as evidenced by Beck Depression score of  $\geq 30$ \*

... and 8 more (see full listing online)

## Locations (1 total)

---

University of Michigan, Ann Arbor, Michigan, United States